摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-Methylphenoxy)-3-pyrrolidin-1-ylpropan-2-ol

中文名称
——
中文别名
——
英文名称
1-(4-Methylphenoxy)-3-pyrrolidin-1-ylpropan-2-ol
英文别名
——
1-(4-Methylphenoxy)-3-pyrrolidin-1-ylpropan-2-ol化学式
CAS
——
化学式
C14H21NO2
mdl
MFCD02928975
分子量
235.32
InChiKey
CHVBUZXSWTYODQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    17
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.571
  • 拓扑面积:
    32.7
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • Carboline Derivatives Useful in the Inhibition of Angiogenesis
    申请人:MOON Young-Choon
    公开号:US20070281962A2
    公开(公告)日:2007-12-06
    In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.
    根据本发明,已经鉴定出了抑制VEGF转录后表达的化合物,并提供了它们的使用方法。在本发明的一个方面,提供了在抑制VEGF产生、抑制血管生成和/或治疗癌症、糖尿病视网膜病变或渗出性黄斑变性方面有用的化合物。在本发明的另一个方面,提供了使用本发明中的化合物抑制VEGF产生、抑制血管生成和/或治疗癌症、糖尿病视网膜病变或渗出性黄斑变性的方法。
  • CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS
    申请人:Moon Young-Choon
    公开号:US20100179132A1
    公开(公告)日:2010-07-15
    In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.
    根据本发明,已经鉴定出抑制VEGF在转录后表达的化合物,并提供了它们的使用方法。本发明的一方面提供了用于抑制VEGF生产、治疗实体肿瘤癌和减少血浆和/或肿瘤VEGF平的化合物。本发明的另一方面提供了使用本发明中的化合物抑制VEGF生产、治疗癌症和减少血浆和/或肿瘤VEGF平的方法。
  • Carboline derivatives useful in the treatment of cancer
    申请人:PTC Therapeutics, Inc.
    公开号:EP2298304A2
    公开(公告)日:2011-03-23
    In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.
    根据本发明,已鉴定出转录后抑制血管内皮生长因子表达的化合物,并提供了使用这些化合物的方法。在本发明的一个方面,提供了用于抑制血管内皮生长因子产生、治疗实体瘤癌症以及降低血浆和/或肿瘤血管内皮生长因子平的化合物。在本发明的另一方面,提供了使用本发明化合物抑制 VEGF 生成、治疗癌症以及降低血浆和/或肿瘤 VEGF 平的方法。
  • Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect
    申请人:Friedrich-Alexander-Universität Erlangen-Nürnberg
    公开号:US10828281B2
    公开(公告)日:2020-11-10
    The present invention is directed to compounds, tautomers, stereoisomers, and chemically modified compounds thereof, and their use in preventing and/or treating tumors of metastasis and/or cartilage defect, and to a pharmaceutical composition comprising such compound.
    本发明涉及其化合物、同系物、立体异构体和化学修饰化合物,及其在预防和/或治疗肿瘤转移和/或软骨缺损中的用途,以及包含此类化合物的药物组合物。
  • ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES
    申请人:Cao Liangxian
    公开号:US20100158858A1
    公开(公告)日:2010-06-24
    In accordance with the present invention, compounds are provided which are useful in a method or in the manufacture of a medicament for post-transcriptionally inhibiting the expression of VEGF in a subject in need thereof comprising inhibiting VEGF mRNA translation by orally administering said medicament once, twice or thrice daily to the subject.
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯